Characterizing rare ENV-expressing cells from people with HIV virally suppressed on art: filling the GAP to inform ENV-targeted cure strategies

Active Grant Awarded

Award ID
R01AI197950
Recipient
Awarding agency
Obligated
$586,448

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 4% complete
Place of performance
2323 Riverside Dr., Ottawa, ON K1H 1A1, Canada

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, awarded Grant R01AI197950 to Sante Quebec Centre Hospitalier De L'universite De Montreal, doing business as CHUM, LE, obligating $586,448 on September 18, 2026 under Assistance Listing 93.855, Allergy and Infectious Diseases Research. The project characterizes rare HIV-1 envelope (Env)-expressing cells in people with HIV who are virally suppressed on antiretroviral therapy, with the aim of informing Env-targeted cure strategies. Its central method is ENV-FLOW, which combines a small CD4-mimetic molecule with three non-neutralizing antibodies targeting CD4-induced epitopes to detect these cells after latency reversal. The source reports preliminary ENV-FLOW results showing a paucity of Env expression on reactivated cells from ART-treated individuals, in contrast to cells from viremic individuals. The recipient's Research Center division is identified as the performing unit. Performance runs from the September 18, 2026 award date to an ultimate completion date of August 31, 2031, with place of performance at 2323 Riverside Dr., Ottawa, Ontario, Canada.

Description

Abstract
More than 1.2 million people live with HIV in the US. Although antiretroviral therapy (art) significantly extends the lifespan of people with HIV-1 (PWH), IT does not eliminate the virus. In addition, art does not fully prevent the long-term complications associated with persistent infection, which causes suffering and financial burden on american people living with HIV. Despite optimal art, HIV-1 proviruses persist in long-lived reservoirs, allowing the virus to rebound rapidly, typically within days to weeks following treatment interruption. Identifying and characterizing the cells in which the virus persists is crucial for developing strategies to efficiently eliminate them. While several eradication strategies target the HIV-1 envelope glycoproteins (ENV), methods that can reliably detect this glycoprotein are lacking. As a result, little is known about the nature of cells expressing ENV upon reactivation, notably regarding their susceptibility to antibody-mediated killing. To fill this GAP, we developed ENV-flow, a technique that allows the reliable detection of these rare ENV-expressing cells following latency reversal. This method combines a potent small CD4-mimetic (CD4MC) molecule and three non-neutralizing antibodies (NNABS) targeting highly conserved CD4-induced (CD4I) epitopes. Although some latency-reversing agents (LRAS) induce P24 expression, their ability to stimulate ENV expression remains unclear. Our preliminary results with ENV-flow revealed a paucity of ENV expression at the surface of reactivated cells from PWH on art, which is in sharp contrast to ENV expression on cells from viremic individuals. The mechanisms underlying the differential expression of ENV between productively infected cells and reactivated cells from art-treated individuals remain to be elucidated. We hypothesize that cellular and/or virological blocks prevent ENV expression at the surface of reservoir cells from art-treated PWH, even after reactivation of latently infected cells, thereby hampering the ability of antibody-mediated immunity to clear viral reservoirs. In this application, we will use a novel technology, ENV-flow, to generate a detailed picture of reactivated ENV-expressing reservoirs. This will fill a knowledge GAP of HIV-1 reservoir cells and will inform cure strategies that are currently being tested in the US. This will be achieved using a multifaceted approach involving immunological, biophysical, structural, and virological analyses.

Quick answers

Who received award R01AI197950?

R01AI197950 was awarded to Sante Quebec Centre Hospitalier De L'universite De Montreal by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 18, 2026.

How much is award R01AI197950 worth?

$586,448 has been obligated on R01AI197950.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award